Recursion Pharmaceuticals (NASDAQ: RXRX) continues to navigate a complex financial landscape, marked by recent insider trading activity and a stock price hovering near its yearly lows. On March 17, 2026, Chief Financial Officer Ben R. Taylor sold 7,956 shares of Class A common stock. The transaction, executed at an average price of $3.39 per share, totaled approximately $26,970.
This sale comes at a delicate time for the Salt Lake City-based biotech firm. Over the past year, Recursion’s valuation has plummeted by 48%, currently trading uncomfortably close to its 52-week low of $2.98. Despite the optics of an executive sell-off during a downturn, the move was not a spontaneous market exit. According to a Form 4 filing with the SEC, the divestment was carried out under a Rule 10b5-1 trading plan established back in September 2025. Such plans are typically set up in advance to allow insiders to sell a predetermined number of shares at set times, providing a layer of protection against accusations of insider trading. Following this transaction, Taylor still maintains a substantial stake in the company, holding over 1.18 million shares directly.
Tax Obligations and Compensation Adjustments
The CFO’s recent activity wasn’t limited to open-market sales. On March 16, the company withheld 7,075 shares from Taylor—valued at roughly $24,196—to satisfy tax withholding obligations triggered by the vesting of Restricted Stock Units (RSUs). These “sell-to-cover” transactions are standard practice in corporate compensation, ensuring that tax liabilities are met as equity awards convert into spendable assets.
While the stock’s recent performance has been sluggish, some analysts suggest the market might be overreacting. InvestingPro data indicates that RXRX may actually be undervalued at its current price point. The company’s balance sheet remains a point of interest for investors, especially as it maintains a market capitalization of $1.81 billion against a backdrop of high short interest, which currently sits at 36.2% of its float.
Beating Expectations in the Fourth Quarter
On the operational front, Recursion’s recent earnings report offered a much-needed silver lining. The company outperformed Wall Street’s expectations for the fourth quarter of 2025, posting an earnings per share (EPS) loss of $0.21—significantly narrower than the $0.30 loss analysts had projected. Revenue was another bright spot, hitting $35.54 million and crushing estimates by 45%.
This financial beat underscores the progress of Recursion’s unique business model. Founded in 2013 by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li, the company isn’t a traditional drug hunter. Instead, it operates a high-tech “operating system” that merges automation and artificial intelligence to decode biological patterns. By using machine learning to predict how drugs will interact with the human body, Recursion aims to identify novel chemistry and potential toxicities faster than conventional methods.
The Long Road to Clinical Validation
Despite the strong quarterly numbers, institutional caution remains. BofA Securities recently adjusted its price target for RXRX, moving it from $7.00 down to $6.00 while maintaining a “Neutral” rating. The adjustment reflects a broader sentiment that while the AI-driven approach is promising, the true clinical value of the pipeline may not fully materialize until at least 2027.
For a clinical-stage company with a high beta of 2.30, volatility is par for the course. Recursion is essentially a bet on the future of “digital biology,” and while the current $3.32 share price reflects immediate market skepticism, the company is banking on its AI capabilities to eventually deliver the breakthrough therapeutics that will justify its ambitious mission.
